Division of Cardiology, Vanderbilt University Medical Center, Nashville, Tenn., USA.
Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tenn., USA.
Cardiorenal Med. 2015 Feb;5(1):48-60. doi: 10.1159/000369589. Epub 2015 Jan 9.
Left ventricular assist devices (LVADs) are used increasingly as a bridge to transplantation or as destination therapy in end-stage heart failure patients who do not respond to optimal medical therapy. Many of these patients have end-organ dysfunction, including advanced kidney dysfunction, before and after LVAD implantation. Kidney dysfunction is a marker of adverse outcomes, such as increased morbidity and mortality. This review discusses kidney dysfunction and associated management strategies during the dynamic perioperative time period of LVAD implantation. Furthermore, we suggest potential future research directions to better understand the complex relationship between renal pathophysiology and mechanical circulatory support.
左心室辅助装置(LVAD)越来越多地被用于终末期心力衰竭患者,作为移植的桥梁或作为对最佳药物治疗无反应的终末治疗。这些患者中的许多人在植入 LVAD 之前和之后都有终末器官功能障碍,包括肾功能障碍。肾功能障碍是不良预后的标志物,例如发病率和死亡率增加。这篇综述讨论了在 LVAD 植入的动态围手术期期间肾功能障碍和相关管理策略。此外,我们提出了一些潜在的未来研究方向,以更好地理解肾脏病理生理学和机械循环支持之间的复杂关系。